Institutions | About Us | Help | Gaeilge
rian logo


Mark
Go Back
Phase ib study of the flt3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
Stone, R M; Fischer, T; Paquette, R; Schiller, G; Schiffer, C A; Ehninger, G; Cortes, J; Kantarjian, H M; DeAngelo, D J; Huntsman-Labed, A; Dutreix, C; del Corral, A; Giles, F
This phase 1b trial investigated several doses and schedules of midostaurin in combination with daunorubicin and cytarabine induction and high-dose cytarabine post-remission therapy in newly diagnosed patients with acute myeloid leukemia (AML). The discontinuation rate on the 50-mg twice-daily dose schedule was lower than 100 mg twice daily, and no grade 3/4 nausea or vomiting was seen. The complete remission rate for the midostaurin 50-mg twice-daily dose schedule was 80% (FMS-like tyrosine kinase 3 receptor (FLT3)-wild-type: 20 of 27 (74%), FLT3-mutant: 12 of 13 (92%)). Overall survival (OS) probabilities of patients with FLT3-mutant AML at 1 and 2 years (0.85 and 0.62, respectively) were similar to the FLT3-wild-type population (0.78 and 0.52, respectively). Midostaurin in combination with standard chemotherapy demonstrated high complete response and OS rates in newly diagnosed younger adults with AML, and was generally well tolerated at 50mg twice daily for 14 days. A phase III prospective trial is ongoing (CALGB 10603, NCT00651261).
Keyword(s): fms-like tyrosine kinase 3 receptor; acute myeloid leukemia; midostaurin; pkc412; newly diagnosed; acute myelogenous leukemia; risk myelodysplastic syndrome; internal tandem duplications; poor-prognosis; mutant flt3; wild-type; group-b; mutations; cytogenetics
Publication Date:
2018
Type: Journal article
Peer-Reviewed: Unknown
Institution: NUI Galway
Publisher(s): Springer Nature
First Indexed: 2019-03-23 07:03:06 Last Updated: 2019-03-23 07:03:06